Compare Jones Lang LaSalle Inc (JLL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Medtronic PLC — how do they compare? Jones Lang LaSalle Inc trades at $300.51 (market cap $13.95B), while Medtronic PLC trades at $88.02 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 8× Jones Lang LaSalle Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Medtronic PLC for 63 Days on average.
| JLL | MDT | |
|---|---|---|
Market Cap | $13.95B | $112.24B |
Volume | 457,462 | 105,663,236 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $105.35 |
52-Week Low | $280.16 | $73.75 |
Typical Hold Time | 71 Days | 63 Days |
Enterprise Value | $16.71B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.99, up 1.12% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $26.12B in 2025, and net income improved to $792.10M. Analyst consensus is bullish with a $450.50 price target, though technical indicators show resistance near $300.
JLL presents a compelling growth opportunity with improving profitability and a reasonable valuation (P/E 14.54). Risks include market volatility and execution challenges in real estate services. The stock's upside potential is supported by analyst optimism and strong cash flow trends, but investors should monitor Q3 earnings for confirmation of growth trajectory.
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
